Clarus Securities Reaffirms “Buy” Rating for Teradyne (CNSX:TER)

Clarus Securities reaffirmed their buy rating on shares of Teradyne (CNSX:TERGet Rating) in a report issued on Monday, Stock Target Advisor reports. They currently have a $11.00 price target on the stock.

Separately, ATB Capital lowered their target price on shares of Teradyne to $11.00 and set a sector perform rating on the stock in a research note on Thursday, April 7th.

About Teradyne (Get Rating)

TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. It produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis infused artisan edibles. The company also operates three retail dispensaries under the Apothecarium brand name in California and Pennsylvania.

Read More

Receive News & Ratings for Teradyne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teradyne and related companies with's FREE daily email newsletter.